Oral pregabalin as an add-on treatment for status epilepticus.

Détails

ID Serval
serval:BIB_9E2DB708AAC5
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Oral pregabalin as an add-on treatment for status epilepticus.
Périodique
Epilepsia
Auteur⸱e⸱s
Novy J., Rossetti A.O.
ISSN
1528-1167 (Electronic)
ISSN-L
0013-9580
Statut éditorial
Publié
Date de publication
10/2010
Peer-reviewed
Oui
Volume
51
Numéro
10
Pages
2207-2210
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article
Publication Status: ppublish
Résumé
Oral antiepileptic drugs (AEDs) represent possible add-on options in refractory status epilepticus (SE). In this setting, pregabalin (PGB) has not been reported before. Over the last 42 months, we identified 11 SE episodes (10 patients) treated with PGB in our hospital. Its use was prompted by the favorable pharmacokinetic profile, devoid of drug-drug interactions. The patients mostly had refractory, partial SE. Only two patients were managed in the intensive care unit (ICU). We found a definite electroclinical response in 5 of 11, already evident 24 h after PGB introduction, and a possible response (concomitantly with other AEDs) in 3 of 11 of the episodes; 3/11 did not respond. The treatment was well tolerated. Partial SE appeared to better respond than generalized convulsive SE. PGB appears to be an interesting option as add-on treatment in refractory partial SE.

Mots-clé
Administration, Oral, Adult, Aged, Aged, 80 and over, Anticonvulsants/administration & dosage, Anticonvulsants/therapeutic use, Drug Resistance, Drug Therapy, Combination, Epilepsies, Partial/drug therapy, Female, Humans, Male, Middle Aged, Pregabalin, Prospective Studies, Status Epilepticus/drug therapy, Treatment Outcome, gamma-Aminobutyric Acid/administration & dosage, gamma-Aminobutyric Acid/analogs & derivatives, gamma-Aminobutyric Acid/therapeutic use
Pubmed
Web of science
Open Access
Oui
Création de la notice
04/11/2010 11:21
Dernière modification de la notice
20/08/2019 16:04
Données d'usage